- Home
- UGRO vs COCP Comparison
UGRO vs COCP Comparison
Compare UGRO & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- COCP
- Stock Information
- Founded
- UGRO 2014
- COCP N/A
- Country
- UGRO United States
- COCP United States
- Employees
- UGRO N/A
- COCP N/A
- Industry
- UGRO Industrial Specialties
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- COCP Health Care
- Exchange
- UGRO Nasdaq
- COCP Nasdaq
- Market Cap
- UGRO 18.0M
- COCP 18.3M
- IPO Year
- UGRO N/A
- COCP N/A
- Fundamental
- Price
- UGRO $0.98
- COCP $1.99
- Analyst Decision
- UGRO Strong Buy
- COCP Strong Buy
- Analyst Count
- UGRO 2
- COCP 1
- Target Price
- UGRO $5.63
- COCP $7.00
- AVG Volume (30 Days)
- UGRO 54.0K
- COCP 14.9K
- Earning Date
- UGRO 12-27-2024
- COCP 11-13-2024
- Dividend Yield
- UGRO N/A
- COCP N/A
- EPS Growth
- UGRO N/A
- COCP N/A
- EPS
- UGRO N/A
- COCP N/A
- Revenue
- UGRO $70,320,066.00
- COCP N/A
- Revenue This Year
- UGRO $14.76
- COCP N/A
- Revenue Next Year
- UGRO $21.29
- COCP N/A
- P/E Ratio
- UGRO N/A
- COCP N/A
- Revenue Growth
- UGRO 12.08
- COCP N/A
- 52 Week Low
- UGRO $0.93
- COCP $1.33
- 52 Week High
- UGRO $2.84
- COCP $3.10
- Technical
- Relative Strength Index (RSI)
- UGRO 23.94
- COCP 51.27
- Support Level
- UGRO $1.17
- COCP $1.83
- Resistance Level
- UGRO $1.19
- COCP $2.07
- Average True Range (ATR)
- UGRO 0.11
- COCP 0.11
- MACD
- UGRO -0.03
- COCP -0.01
- Stochastic Oscillator
- UGRO 7.81
- COCP 44.74
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).